Showing results (181-190 of 336) with videos related to

Sort By:
Pageof 34
European Journal of Cancer (Oxford, England : 1990)|February 21, 1998
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II studyC H Köhne, A Harstrick, W Hiddemann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 17, 2007
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study GroupC Bokemeyer, K Oechsle, F Honecker, et al.
Actas Urologicas Espanolas|December 23, 2011
[EAU guidelines on testicular cancer: 2011 update. European Association of Urology]P Albers, W Albrecht, F Algaba, et al.
British Journal of Urology|July 1, 1997
Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancerM A Kuczyk, C Bokemeyer, G Köhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Treatment of brain metastases in patients with testicular cancerC Bokemeyer, P Nowak, A Haupt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2002
A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumorsF Mayer, J T Hartmann, J von Pawel, et al.
Oncology (Williston Park, N.Y.)|December 1, 2000
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumorsC Bokemeyer, J T Hartmann, F Mayer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 1995
p53 overexpression as a prognostic factor for advanced stage bladder cancerM A Kuczyk, C Bokemeyer, J Serth, et al.
Arzneimittel-Forschung|March 1, 1993
Pen-based remote data entry system. A pilot clinical trialI Beinlich, C Bokemeyer, U Räth, et al.
British Journal of Cancer|December 1, 1996
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activityC Bokemeyer, L M Fels, T Dunn, et al.
Pageof 34